Roche Sequencing
Roche Sequencing is the next-generation sequencing product line within Roche Diagnostics, selling KAPA library prep, AVENIO assays and automation, navify and FoundationOne analysis software, and the in-development AXELIOS 1 sequencer based on proprietary Sequencing by Expansion chemistry to research, clinical, and pharma customers worldwide.
- Company typePublic
- Founded1896
- HeadquartersPleasanton, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Roche Sequencing does
Roche Sequencing is a product category within Roche Diagnostics, the diagnostics division of F. Hoffmann-La Roche Ltd (founded 1896, listed on the SIX Swiss Exchange under ROG). Headquartered in Basel, Switzerland, with North American operations in Pleasanton, California, the unit sells next-generation sequencing (NGS) solutions to research institutions, clinical laboratories, and pharmaceutical companies globally through Roche Diagnostics' direct enterprise sales force and online ordering portal.
The portfolio is organized as an end-to-end workflow. Sample preparation is anchored by KAPA library prep kits (EvoPrep, EvoPlus, RNA EvoPrep), KAPA HyperExome V2 target enrichment probes, and the HyperDesign custom panel design tool. The AVENIO Edge System provides walk-away IVD-grade automation for library prep, target enrichment, quantification, and pooling, while AVENIO Tumor Tissue CGP and ctDNA Expanded kits deliver oncology-focused comprehensive genomic profiling assays. Data analysis is handled by cloud software including navify Mutation Profiler for tertiary interpretation and the FoundationOne Analysis Platform for secondary analysis. The flagship strategic asset is the AXELIOS 1 Sequencing Platform — currently in development — built on proprietary Sequencing by Expansion (SBX) chemistry, positioned for high-accuracy, high-throughput Research Use Only sequencing with an SBX-Fast workflow targeting approximately 5 hours from sample to VCF.
The business model combines hardware sales (AXELIOS 1 sequencer, AVENIO Edge System) with recurring consumables revenue (KAPA kits, AVENIO assays) and cloud-based software subscriptions (navify, FoundationOne). Pricing is not publicly disclosed and is quote-based through Roche Diagnostics' commercial channels. GTM is enterprise field sales supported by technical specialists and an online service portal (eLabDoc). Distribution leverages Roche's global manufacturing footprint, and the unit is actively building an ecosystem through integrations with third-party automation vendors (Volta Labs) and co-development partners (Watchmaker Genomics). Specific revenue figures for Roche Sequencing are not publicly disclosed.
Roche Sequencing firmographics
Firmographics- Name
- Roche Sequencing
- Legal name
- F. Hoffmann-La Roche Ltd
- Website
- https://sequencing.roche.com
- Company type
- Public
- Founded year
- 1896
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Roche Sequencing is the next-generation sequencing product line within Roche Diagnostics, selling KAPA library prep, AVENIO assays and automation, navify and FoundationOne analysis software, and the in-development AXELIOS 1 sequencer based on proprietary Sequencing by Expansion chemistry to research, clinical, and pharma customers worldwide.
- Ownership category
- akta.pro rank
Roche Sequencing industry classification
Industry- Product category
- Next-Generation Sequencing Solutions
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
- akta.pro secondary industries
- Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
Keywords
Where Roche Sequencing is headquartered
LocationHeadquarters
- HQ city
- Pleasanton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Roche Sequencing business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- NGS Instruments and Platforms: Sale of sequencing instruments including the AXELIOS 1 platform (in development) and AVENIO Edge System automation hardware for IVD and research use.
- Sequencing Reagents and Kits: KAPA library preparation kits, target enrichment panels, and AVENIO CGP assay kits sold as recurring consumables for NGS workflows.
- Software Licenses: Cloud-based software solutions including navify Mutation Profiler, FoundationOne Analysis Platform, and AVENIO Oncology Analysis Software for data analysis.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Roche Sequencing product offering
Product offeringCore offering
Roche Sequencing sells an end-to-end next-generation sequencing (NGS) portfolio covering KAPA DNA/RNA library preparation kits, KAPA target enrichment panels and probes, the AVENIO Edge System for automated sample prep, AVENIO comprehensive genomic profiling assays for oncology research, cloud-based analysis software (navify Mutation Profiler, AVENIO Oncology Analysis Software, FoundationOne Analysis Platform), and the in-development AXELIOS 1 Sequencing Platform based on its proprietary Sequencing by Expansion (SBX) chemistry. Products are sold as instruments, recurring reagent/consumable kits, and software licenses to research institutions, clinical laboratories, and pharmaceutical companies worldwide.
Product overview
Roche Sequencing offers a comprehensive portfolio of next-generation sequencing (NGS) solutions organized into integrated modules covering the entire sequencing workflow from sample preparation to data analysis. The portfolio is anchored by the KAPA library preparation and target enrichment solutions for efficient sample prep, the AVENIO Edge System for walk-away automation, AVENIO comprehensive genomic profiling (CGP) assays for oncology research, the AXELIOS 1 Sequencing Platform powered by proprietary Sequencing by Expansion (SBX) technology, and cloud-based data analysis tools including navify Mutation Profiler, AVENIO Oncology Analysis Software, and FoundationOne Analysis Platform. The AXELIOS 1 platform, based on innovative SBX technology, is designed to deliver unprecedented speed and flexibility for research applications. Third-party partnerships enable integration with external analysis platforms and liquid handling systems.
Differentiator
Problem solved
Functional benefit
Brands
- KAPA: KAPA library preparation and target enrichment solutions for NGS workflows, including KAPA EvoPrep Kits, KAPA EvoPlus Kits, KAPA RNA EvoPrep Kits, and KAPA HyperExome V2 Probes.
- AVENIO
- AXELIOS
- navify
- FoundationOne
Products and services
- KAPA EvoPrep Kits NGS library preparation kits that enable pre-fragmented DNA library preparation for whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted sequencing, and methyl-seq with a streamlined, fully automatable workflow. Targeted at research and clinical laboratories performing NGS workflows.
- KAPA EvoPlus Kits High-performance DNA library preparation kits with enhanced enzymatic fragmentation and a streamlined, fully automatable workflow, for laboratories requiring reliable NGS library prep.
- KAPA RNA EvoPrep Kits RNA library preparation kits designed to shorten workflow, boost sequencing efficiency, capture more unique transcripts, and accelerate RNA-based discovery research for genomics laboratories.
- KAPA HyperExome V2 Probes and Kits Whole Exome Sequencing target enrichment probe and kit solution delivering superior content coverage for WES applications in research and clinical genomics.
- HyperDesign Custom design tool for KAPA Target Enrichment workflows, combining KAPA target enrichment chemistry with Roche's probe and primer design expertise to design custom NGS panels.
- AVENIO Edge System Fully automated IVD liquid handler for end-to-end library preparation, target enrichment, quantification, normalization, and pooling, combining Roche NGS expertise with pre-analytical automation experience for clinical and research laboratories.
- AVENIO Designer Intuitive, templated design software for rapid and flexible user-defined workflow deployment on the AVENIO Edge System, with tunable parameters and validated workflows.
- AXELIOS 1 Sequencing Platform High-throughput, transformative Research Use Only (RUO) sequencing platform powered by Sequencing by Expansion (SBX) technology, delivering accurate, cost-effective sequencing across a wide range of research applications at unprecedented scale and speed. SBX-Fast workflow enables DNA sequencing from sample to VCF in approximately 5 hours.
- navify Mutation Profiler Research use only cloud-based software for interpretation of genomic alterations and signatures generated from sequencing DNA isolated from FFPE tumor tissue and liquid biopsy specimens, annotating somatic alterations with information from curated literature, databases, guidelines, drug labels, and clinical trials.
- AVENIO Tumor Tissue CGP Kit V2 In-house next-generation sequencing (NGS) research assay providing comprehensive genomic profiling of solid tumors from formalin-fixed tissue specimens for oncology research.
- AVENIO Tumor Tissue CGP Automated Kit Next-generation sequencing (NGS) assay for comprehensive genomic profiling (CGP) of solid tumors with automated workflow on the AVENIO Edge System for oncology research laboratories.
- AVENIO ctDNA Expanded Kit V2 NGS liquid biopsy research assay for lung cancer, colorectal cancer, and pan-cancer research using circulating tumor DNA from plasma.
Quantifiable outcome
- SBX-Fast workflow enables DNA sequencing from sample to VCF in approximately 5 hours
- +2 more outcomes
Companies that use Roche Sequencing
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Roche Sequencing technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature7 records
Roche Sequencing partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Volta LabscoreVolta Labs announced integration of its Callisto platform with Roche Sequencing's AXELIOS 1 system at AGBT 2026. The integration enables automated genomics workflows combining Callisto's automation capabilities with Roche's SBX sequencing technology. UMC Utrecht and Hartwig Medical Foundation presented production-scale validation data showing thousands of patient samples processed with improved consistency and operational efficiency over nearly a year of deployment.
- Watchmaker GenomicsminorLaunched a PCR-free whole genome sequencing kit developed in collaboration with Watchmaker Genomics, expanding the ecosystem of solutions available for the Callisto platform and AXELIOS 1 system.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Roche Sequencing competitors and assessment
Company assessmentDirect peers
- Illumina: Dominant short-read NGS platform provider (NovaSeq, NextSeq, iSeq) with a full sequencing-by-synthesis workflow; directly competes with Roche Sequencing's AXELIOS 1 and KAPA/AVENIO consumables for research and clinical lab customers.
- Thermo Fisher Scientific: Operates the Ion Torrent sequencing platform plus an extensive NGS reagents and target-enrichment portfolio (Ion AmpliSeq, Oncomine); competes head-to-head with Roche across sequencing instruments, library prep, and oncology assays.
- Element Biosciences: Developer of the AVITI benchtop NGS platform using an alternative sequencing chemistry; targets many of the same translational and clinical research labs that Roche's AXELIOS 1 and KAPA reagents are pursuing.
- Singular Genomics: Provides the G4 benchtop NGS sequencer with a unique four-flow-cell architecture, competing directly with Roche's modular/flexible sequencing pitch to mid-throughput research customers.
- Pacific Biosciences: Long-read sequencing platform (Revio, Onso) now expanding into short-read oncology research, increasingly competing with Roche's NGS assays and AXELIOS 1 across translational genomics.
- Oxford Nanopore Technologies: Long-read/native nucleic acid sequencing platform (PromethION, GridION) competing for translational and clinical research applications where Roche's KAPA HyperExome and AXELIOS 1 also compete for share.
Broad incumbents
- QIAGEN: Diversified sample-prep and molecular diagnostics provider (QIAseq target enrichment, GeneReader) overlapping with Roche's KAPA library prep, AVENIO assays, and bioinformatics offering.
- Bio-Rad Laboratories: Provides Droplet Digital PCR and life science research tools with adjacent NGS workflows; competes at the bench-research and translational lab level where Roche sells KAPA reagents.
Emerging players
- Ultima Genomics: Early-stage sequencing platform targeting ultra-low-cost high-throughput sequencing, positioning against AXELIOS 1 in the large-scale genomics research market.
- MGI Tech (BGI Group): Provides DNBSEQ sequencing platforms and related reagents with broad global (especially APAC) reach; competes with Roche Sequencing instruments and consumables in international markets.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Roche Sequencing social profiles
Digital presenceRoche Sequencing financial estimates
Financial estimateRevenue estimate
Valuation estimate
Roche Sequencing leadership team
Management profileNumber of profiles
Roche Sequencing funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Roche Sequencing M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Roche Sequencing
What does Roche Sequencing do?
Roche Sequencing sells an end-to-end next-generation sequencing (NGS) portfolio covering KAPA DNA/RNA library preparation kits, KAPA target enrichment panels and probes, the AVENIO Edge System for automated sample prep, AVENIO comprehensive genomic profiling assays for oncology research, cloud-based analysis software (navify Mutation Profiler, AVENIO Oncology Analysis Software, FoundationOne Analysis Platform), and the in-development AXELIOS 1 Sequencing Platform based on its proprietary Sequencing by Expansion (SBX) chemistry. Products are sold as instruments, recurring reagent/consumable kits, and software licenses to research institutions, clinical laboratories, and pharmaceutical companies worldwide.
Is Roche Sequencing a public or private company?
Roche Sequencing is a public company. It is classified as public and is currently operating.
When was Roche Sequencing founded?
Roche Sequencing was founded in 1896. It employs 101 to 250 people.
Where is Roche Sequencing based?
Roche Sequencing is headquartered in Pleasanton, United States, in the North America region.
How does Roche Sequencing make money?
Three revenue lines are on record. NGS Instruments and Platforms are the primary driver. The others are sequencing Reagents and Kits and software Licenses.
Who are Roche Sequencing's main competitors?
Direct peers on record are Illumina, Thermo Fisher Scientific, Element Biosciences, Singular Genomics, Pacific Biosciences and Oxford Nanopore Technologies. Broad incumbents are QIAGEN and Bio-Rad Laboratories. Emerging players are Ultima Genomics and MGI Tech (BGI Group).
Does Roche Sequencing have an API?
No public API is recorded for Roche Sequencing.
What industry is Roche Sequencing in?
Roche Sequencing's product category is Next-Generation Sequencing Solutions. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 325413 and its SIC code is 2835.